Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Erol C. Vatansever"'
Autor:
Wenyue Cao, Chia-Chuan Dean Cho, Zhi Zachary Geng, Namir Shaabani, Xinyu R. Ma, Erol C. Vatansever, Yugendar R. Alugubelli, Yuying Ma, Sankar P. Chaki, William H. Ellenburg, Kai S. Yang, Yuchen Qiao, Robert Allen, Benjamin W. Neuman, Henry Ji, Shiqing Xu, Wenshe Ray Liu
Publikováno v:
ACS Central Science, Vol 8, Iss 2, Pp 192-204 (2022)
Externí odkaz:
https://doaj.org/article/f8e6bc3a68de4550a1f279b547e4da04
Autor:
Kaustav Khatua, Yugendar R. Alugubelli, Kai S. Yang, Veerabhadra R. Vulupala, Lauren R. Blankenship, Demonta D. Coleman, Sandeep Atla, Sankar P. Chaki, Zhi Zachary Geng, Xinyu R. Ma, Jing Xiao, Peng-Hsun Chase Chen, Chia-Chuan Dean Cho, Erol C. Vatansever, Yuying Ma, Ge Yu, Benjamin W. Neuman, Shiqing Xu, Wenshe Ray Liu
Publikováno v:
bioRxiv
Main protease (MPro) of SARS-CoV-2, the viral pathogen of COVID-19, is a crucial nonstructural protein that plays a vital role in the replication and pathogenesis of the virus. Its protease function relies on three active site pockets to recognize P1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::216a999fb1a67e7463a682d08f991ad5
https://doi.org/10.1101/2023.04.11.536467
https://doi.org/10.1101/2023.04.11.536467
Autor:
Zhi Zachary Geng, Sandeep Atla, Namir Shaabani, Veerabhadra R. Vulupala, Kai S. Yang, Yugendar R. Alugubelli, Kaustav Khatua, Peng-Hsun Chase Chen, Jing Xiao, Lauren R. Blankenship, Xinyu R. Ma, Erol C. Vatansever, Chia-Chuan Cho, Yuying Ma, Robert Allen, Henry Ji, Shiqing Xu, Wenshe Ray Liu
Publikováno v:
bioRxiv
SARS-CoV-2 is the coronavirus pathogen of the currently prevailing COVID-19 pandemic. It relies on its main protease (MPro) for replication and pathogenesis. MProis a demonstrated target for the development of antivirals for SARS-CoV-2. Past studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac78ca035630d56fd9f723ac192834af
https://europepmc.org/articles/PMC9882326/
https://europepmc.org/articles/PMC9882326/
Autor:
Yuying Ma, Kai S. Yang, Zhi Zachary Geng, Yugendar R. Alugubelli, Namir Shaabani, Erol C. Vatansever, Xinyu R. Ma, Chia-Chuan Cho, Kaustav Khatua, Jing Xiao, Lauren R. Blankenship, Ge Yu, Banumathi Sankaran, Pingwei Li, Robert Allen, Henry Ji, Shiqing Xu, Wenshe Ray Liu
Publikováno v:
European journal of medicinal chemistry. 240
As an essential enzyme of SARS-CoV-2, the COVID-19 pathogen, main protease (M
Autor:
Yugendar R. Alugubelli, Zhi Zachary Geng, Kai S. Yang, Namir Shaabani, Kaustav Khatua, Xinyu R. Ma, Erol C. Vatansever, Chia-Chuan Cho, Yuying Ma, Jing Xiao, Lauren R. Blankenship, Ge Yu, Banumathi Sankaran, Pingwei Li, Robert Allen, Henry Ji, Shiqing Xu, Wenshe Ray Liu
Publikováno v:
European journal of medicinal chemistry. 240
Boceprevir is an HCV NSP3 inhibitor that was explored as a repurposed drug for COVID-19. It inhibits the SARS-CoV-2 main protease (M
Autor:
Xinyu R. Ma, Yugendar R. Alugubelli, Yuying Ma, Erol C. Vatansever, Danielle A. Scott, Yuchen Qiao, Ge Yu, Shiqing Xu, Wenshe Ray Liu
Publikováno v:
ChemMedChem. 17
Autor:
Yuying, Ma, Kai S, Yang, Zhi Zachary, Geng, Yugendar R, Alugubelli, Namir, Shaabani, Erol C, Vatansever, Xinyu R, Ma, Chia-Chuan, Cho, Kaustav, Khatua, Lauren, Blankenship, Ge, Yu, Banumathi, Sankaran, Pingwei, Li, Robert, Allen, Henry, Ji, Shiqing, Xu, Wenshe Ray, Liu
Publikováno v:
bioRxiv
As an essential enzyme to SARS-CoV-2, main protease (M (Pro) ) is a viable target to develop antivirals for the treatment of COVID-19. By varying chemical compositions at both P2 and P3 sites and the N -terminal protection group, we synthesized a ser
Autor:
Yugendar R, Alugubelli, Zhi Zachary, Geng, Kai S, Yang, Namir, Shaabani, Kaustav, Khatua, Xinyu R, Ma, Erol C, Vatansever, Chia-Chuan, Cho, Yuying, Ma, Lauren, Blankenship, Ge, Yu, Banumathi, Sankaran, Pingwei, Li, Robert, Allen, Henry, Ji, Shiqing, Xu, Wenshe Ray, Liu
Publikováno v:
bioRxiv
Boceprevir is an HCV NSP3 inhibitor that has been explored as a repurposed drug for COVID-19. It inhibits the SARS-CoV-2 main protease (M (Pro) ) and contains an α-ketoamide warhead, a P1 β-cyclobutylalanyl moiety, a P2 dimethylcyclopropylproline,
Autor:
Yuying Ma, Kai S. Yang, Zhi Zachary Geng, Yugendar R. Alugubelli, Namir Shaabani, Erol C. Vatansever, Xinyu R. Ma, Chia-Chuan Cho, Kaustav Khatua, Lauren Blankenship, Ge Yu, Banumathi Sankaran, Pingwei Li, Robert Allen, Henry Ji, Shiqing Xu, Wenshe Ray Liu
As an essential enzyme to SARS-CoV-2, main protease (MPro) is a viable target to develop antivirals for the treatment of COVID-19. By varying chemical compositions at both P2 and P3 sites and the N-terminal protection group, we synthesized a series o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86a256ca7271ec5589d0107e6f50110f
https://doi.org/10.1101/2021.12.18.473326
https://doi.org/10.1101/2021.12.18.473326
Autor:
Erol C. Vatansever, Kai S. Yang, Zhi Zachary Geng, Yuchen Qiao, Pingwei Li, Shiqing Xu, Wenshe Ray Liu
Publikováno v:
J Mol Biol
As one of the most valuable tools for genetic code expansion, pyrrolysyl-tRNA synthetase (PylRS) is structurally related to phenylalanyl-tRNA synthetase (PheRS). By introducing mutations that mimic ligand interactions in PheRS into PylRS, we designed